8-K: IMAC Holdings Partners VUMC for Cancer Research

IMAC Holdings' subsidiary, Ignite Proteomics, announced a research collaboration with Vanderbilt University Medical Center to advance immuno-oncology biomarker discovery and issued an $84,000 promissory note.

Summary

• Ignite Proteomics, a wholly owned subsidiary of IMAC Holdings, Inc., entered into a one-year Research Collaboration Agreement with Vanderbilt University Medical Center (VUMC) on August 1, 2025.
• Under the agreement, VUMC will supply up to 80 de-identified FFPE breast-cancer samples, and Ignite will perform reverse phase protein array (RPPA) analysis of priority tumor-immune biomarkers.
• Each party will bear its own costs, with Ignite's contribution being in-kind assay support.
• Ignite receives an exclusive, time-bounded option to negotiate a worldwide license to jointly developed intellectual property.
• The agreement may be terminated on 30 days' notice by either party.
• IMAC Holdings, Inc. issued an unsecured promissory note on August 5, 2025, with an aggregate principal amount of $84,000 for an aggregate purchase price of $60,000.
• The promissory note matures on December 24, 2025, and can be prepaid at any time without penalty.
• A press release announcing the collaboration was issued on August 7, 2025.

Sentiment

Score: 7

Explanation: The collaboration with a prestigious institution like VUMC for advanced cancer research is a significant positive, indicating strategic progress and potential for future intellectual property. However, the issuance of a discounted promissory note suggests ongoing capital needs and financial pressure, tempering overall sentiment.

Positives

• Collaboration with Vanderbilt University Medical Center (VUMC), a global leader in academic medicine and cancer research, enhances credibility and research capabilities for Ignite Proteomics.
• Ignite Proteomics' RPPA platform will be deployed on rigorously annotated clinical samples, potentially leading to significant biomarker discoveries in immuno-oncology.
• An exclusive, time-bounded option for Ignite to negotiate a worldwide license to jointly developed intellectual property offers future commercialization potential.
• The research aims to identify actionable biomarkers to refine immunotherapy strategies and combination regimens, addressing a critical need in oncology.

Negatives

• IMAC Holdings issued an unsecured promissory note with an aggregate principal amount of $84,000 for a purchase price of $60,000, indicating a discount and potential financing challenges.
• The promissory note matures relatively soon, on December 24, 2025, requiring repayment or refinancing in the near term.
• Each party bears its own costs for the collaboration, meaning Ignite Proteomics will incur expenses for its in-kind assay support.

Risks

• The Research Collaboration Agreement may be terminated on 30 days' notice by either party.
• The successful completion of the research project, including the validity and reproducibility of study data, is not guaranteed.
• Regulatory developments could impact the outcomes of the research and potential future commercialization.
• The ability of the parties to negotiate any future license agreement for jointly developed intellectual property is not assured.
• The promissory note includes customary events of default, such as certain types of bankruptcy or insolvency, after which the outstanding principal may be declared immediately due and payable.

Future Outlook

The collaboration with Vanderbilt University Medical Center is expected to advance immuno-oncology biomarker discovery, leveraging Ignite Proteomics' RPPA platform to profile tumor-immune signaling in breast cancer samples. Initial data packages are anticipated within two months of sample receipt. The company also holds an exclusive option to negotiate a worldwide license for any jointly developed intellectual property, potentially leading to future commercialization.

Management Comments

• "Partnering with VUMC's world-class immuno-oncology team allows us to deploy our RPPA platform on rigorously annotated clinical samples." Faith Zaslavsky, President and Chief Executive Officer of Ignite Proteomics.
• "By quantifying many immune-checkpoint and signaling proteins simultaneously, we aim to illuminate mechanisms of response and resistance that genomic and single protein tests alone cannot capture." Faith Zaslavsky.
• "This collaborative study gives us a unique window into tumor-immune interactions in breast cancer. Ignite's pathway-level protein read-outs should accelerate our search for actionable biomarkers that can refine immunotherapy strategies and combination regimens." Dr. Justin Balko, Pharm.D., Ph.D., Principal Investigator at VUMC.

Industry Context

The collaboration addresses the critical need for multi-dimensional biomarker platforms in immuno-oncology, as current single-analyte tests like PD-L1 IHC have limitations, with objective response rates for immune-checkpoint blockade therapies often below 40 percent. Integrating pathway-level protein, genomic, and micro-environment data is essential to better match immunotherapies to patients and improve treatment outcomes, aligning with broader industry efforts to enhance precision oncology.

Comparison to Industry Standards

• The collaboration with Vanderbilt University Medical Center, a global leader in cancer research, positions Ignite Proteomics favorably against smaller biotech firms that may lack access to such high-caliber academic partnerships.
• The focus on multi-dimensional biomarker platforms, integrating pathway-level protein data, aligns with cutting-edge research in precision oncology, moving beyond the limitations of single-analyte tests like PD-L1 IHC, which are common but often insufficient in predicting immunotherapy response.
• The use of Reverse Phase Protein Array (RPPA) technology for quantifying 32 phosphoand total-protein biomarkers from minute biopsy material is a specialized capability that differentiates Ignite Proteomics from companies relying solely on genomic sequencing or immunohistochemistry.

Stakeholder Impact

• Shareholders: Potential for increased value through intellectual property development and commercialization from the VUMC collaboration, but also financial strain from the promissory note and potential future dilution.
• Patients/Healthcare Providers: The research aims to identify actionable biomarkers, potentially leading to more refined immunotherapy strategies and improved patient outcomes in breast cancer.
• Employees (Ignite Proteomics): Increased workload and strategic focus on the collaboration, potentially leading to skill development and scientific advancements.
• Lender: Receives interest/return on the $60,000 investment, with the principal due by December 24, 2025.

Next Steps

• VUMC to supply up to 80 de-identified FFPE breast-cancer samples to Ignite Proteomics.
• Ignite Proteomics to perform reverse phase protein array (RPPA) analysis of the provided samples.
• Initial data packages from the collaboration are expected within 2 months of sample receipt.
• Potential negotiation of a worldwide license for jointly developed intellectual property between Ignite Proteomics and VUMC.
• Repayment or refinancing of the $84,000 promissory note by its maturity date of December 24, 2025.

Key Dates

Recommendation

The research collaboration with Vanderbilt University Medical Center is a significant positive development, offering potential for valuable intellectual property and advancing the company's strategic goals in precision oncology. This could drive long-term value. However, the issuance of a discounted promissory note for $84,000 (for $60,000 received) with a short maturity date (December 24, 2025) indicates immediate financial needs and potential liquidity concerns. While the collaboration is promising, the financing structure suggests underlying financial pressure. Investors should hold to monitor the progress of the research collaboration and the company's ability to manage its short-term debt obligations.

Keywords

Immuno-oncology, Biomarker Discovery, Breast Cancer, RPPA, Ignite Proteomics, Vanderbilt University Medical Center, SEC Filing, 8-K, IMAC Holdings, Promissory Note